2026's Biggest Stock Winners: AI, Healthcare, Consumer & Financials—What's Next?
13 Megacaps, Different Growth Stories: Who Will Lead the Next Rally?
AI chips, healthcare breakthroughs and cash-generating giants are telling very different stories. Which rally has the strongest next chapter?
Hi Tigers!🐯
The biggest stocks are not moving as one. In our selected group of 13 S&P 500 megacaps, Micron and AMD have more than doubled this year, while healthcare names have delivered substantial gains and payment networks have quietly advanced. JPMorgan, meanwhile, is barely positive.
That contrast raises a better question than simply asking which stock has risen most: what must happen to earnings for the next leg higher to make sense?
Let's look beyond the leaderboard and separate AI spending, medical innovation, consumer resilience and capital returns.
1. The Scoreboard: Thirteen Positive Stocks, Very Different Rallies
Source: Upside's November 19, 2026 session snapshot .
YTD figures follow the provider's dividend/split-adjusted methodology; they are not independently calculated price-only returns. Reference prices are that same snapshot, rather than executable quotes. This is a selected watchlist from the largest S&P 500 companies, not an exhaustive list of positive performers or a ranking of the 13 best returns. Berkshire uses Class B shares; Alphabet's share classes should be consolidated when ranking companies.
The S&P 500 price index was up approximately 4.8% through November 19.
Twelve stocks in this group show materially larger reported gains, but JPMorgan does not. Dividend-adjusted stock returns and the price index use different conventions, so the comparison is directional rather than a precise excess-return calculation.
My read: the strongest gains span several earnings engines. This watchlist alone cannot establish that the entire market rally is broadening.
2. Technology: Apple’s Earnings Engine Meets the AI Hardware Boom
-
$Apple(AAPL)$: Can earnings catch up with the share price?
Apple reported fiscal Q4 revenue of $114.5 billion, up 12%, and diluted EPS of $2.10, up 14%. iPhone reached a September-quarter revenue record and Services an all-time high . Those results provide a fundamental explanation for investor confidence: hardware demand and the installed-base business are reinforcing each other.
What could move the stock next? Sustained iPhone growth and Services monetization could support further earnings upgrades. But a good business can still deliver a disappointing stock return if its valuation contracts. I would watch the next earnings outlook and margins before treating every pullback as an opportunity.
-
$Advanced Micro Devices(AMD)$: The rally needs delivery, margins and cash
AMD's Q3 revenue rose 45% to $13.38 billion, while Data Center revenue grew 97%. Non-GAAP EPS reached $2.09, up 74%. That combination helps explain why investors have rewarded the company: data-center scale is translating into faster profit growth.
The next catalyst is execution on Instinct GPUs and EPYC CPUs. My outlook is constructive only if growth continues to produce stronger profitability. Shipment delays, tougher competition or weaker customer spending could compress the multiple even while revenue grows. A stock up more than 100% needs more than an attractive industry story.
-
$Micron Technology(MU)$: Strong memory demand, but beware peak earnings
Micron reported record fiscal 2026 results and said it expected an even stronger fiscal 2027, highlighting AI demand and strategic customer agreements [5]. The investment case is that more capable AI systems need more memory, and tighter supply can improve supplier economics.
The stock-market question is how long those economics last. I would track memory pricing, customer commitments and supply additions together. A low earnings multiple can be deceptive if current profits are near a cycle peak. Continued demand strength supports upside; a supply response could reverse it quickly.
3. Consumer Stocks: Amazon and Walmart Are Different Bets
-
$Amazon.com(AMZN)$: AWS is accelerating; free cash flow is the pressure point
Amazon's Q3 AWS revenue rose 39% to $46.0 billion, while companywide operating income reached $28.1 billion. But trailing-twelve-month free cash flow was a $42.4 billion outflow, reflecting heavy investment.
That tension is central to the stock. Faster cloud growth supports the rally, while capital intensity can limit what shareholders receive today. My positive scenario requires AWS growth and better cash conversion. If infrastructure spending keeps outrunning monetization, an improving operating margin may not be enough to lift the valuation.
-
$Wal-Mart(WMT)$: A defensive retailer with additional growth engines
Walmart's November 19 release showed quarterly revenue up 5.2%, global eCommerce up 17%, advertising up 25%, and membership fee revenue up 17%. The company raised its fiscal 2027 outlook.
Those businesses give investors more to evaluate than store sales alone. My interpretation is that advertising and membership growth can strengthen the earnings mix, alongside the resilience of everyday spending. The risk is paying too much for that resilience. Slower traffic or weaker margins could weigh on shares even if Walmart remains operationally solid.
4. Healthcare: Three Rallies, Three Different Tests
-
$Eli Lilly(LLY)$: Demand growth versus expectations
Lilly's Q3 revenue rose 39% to $24.4 billion, primarily driven by Mounjaro and Zepbound, and it raised full-year revenue guidance to $91–92 billion. That supports a growth-led explanation for its performance.
There is a quality-of-growth detail to watch: approximately $900 million of quarterly revenue benefits came mainly from milestones and favorable rebate/discount estimate adjustments. Further upside depends on sustained underlying demand, supply execution and attractive realized pricing. Strong prescription growth with weaker economics would be a less convincing catalyst.
-
$Johnson & Johnson(JNJ)$: A stronger outlook, with a large GAAP caveat
Johnson & Johnson's Q3 sales rose 5.9% to $25.4 billion, and it raised its full-year adjusted EPS guidance midpoint to $11.10. However, GAAP EPS was just $0.09, reflecting special charges and transaction impacts; adjusted EPS was $2.59.
My interpretation is that confidence in the portfolio and outlook has supported the shares, rather than a clean surge in reported quarterly profit. The next leg needs continued operating growth and clarity on litigation exposure. JNJ's rally should not be described as proof that legal risk has disappeared.
-
$AbbVie(ABBV)$: Newer drugs are carrying more weight
AbbVie's Q3 revenue rose 10.3% to $17.40 billion. Skyrizi sales increased 22.7% and Rinvoq 23.9%, while Humira fell 31.2%. Full-year adjusted EPS guidance rose to $13.95–13.99.
This provides a concrete explanation for the rally: growth products are offsetting a major legacy decline. I would watch whether that replacement engine keeps producing upgrades. Slower Skyrizi/Rinvoq growth, pricing pressure or pipeline setbacks would weaken the case for further gains.
5. Financials: Banks, Payment Networks and Berkshire Need Separate Lenses
-
$JPMorgan Chase(JPM)$: Positive does not mean a market leader
JPMorgan reported $15.3 billion in Q3 net income and $50.9 billion in managed revenue. Average loans rose 10% and deposits 8% year over year. Those figures support the case for a substantial operating franchise, but its +1.30% reported YTD return is the weakest in this group.
For a stronger stock performance, I would look for better earnings expectations without deterioration in credit quality. Rising credit costs, deposit competition or expense pressure could offset revenue strength. JPM is the caution against forcing every selected stock into the same “big winner” narrative.
-
$Visa(V)$ and $MasterCard(MA)$: The spending networks have different risks from lenders
Visa's fiscal Q4 net revenue increased 13% to $12.1 billion; payments volume rose 9% and cross-border volume excluding intra-Europe rose 14%. Mastercard's Q3 net revenue increased 14% to $9.8 billion, with cross-border volume up 11%.
These network metrics provide earnings support for both rallies. Their models depend primarily on payment activity and services rather than holding consumer card loans like an issuing bank. My next-leg test is sustained volume growth with healthy margins. Weaker spending, regulation, client incentives and alternative payment methods remain relevant valuation risks.
-
$Berkshire Hathaway(BRK.B)$: Buybacks support the story, but operating profit fell
Berkshire repurchased approximately $9.6 billion of shares in Q3. Yet operating earnings fell to $12.71 billion from $13.49 billion a year earlier.
My interpretation is that capital allocation and the diversified business mix help explain investor interest, but buybacks do not prove the stock is undervalued. For further upside, I would look for operating improvement and attractive deployment of capital. Insurance losses and weaker investment income can still weigh on results.
6. XOM: Cash Generation Supports the Rally—Commodity Prices Still Matter
ExxonMobil reported Q3 earnings of $15.4 billion, operating cash flow of $25.7 billion, and free cash flow of $19.1 billion. Quarterly shareholder distributions totaled $9.4 billion.
That cash generation supports dividends and repurchases, offering a different investment rationale from AI growth. Stronger production and cost execution help, but favorable commodity prices and refining margins also contributed.
My outlook depends on cash flow holding up through changing energy prices. If oil weakens, investors should reassess earnings power and distribution coverage rather than assume the past year's gain will repeat.
7. The Hidden Connection: One Company’s Spending Is Another’s Revenue
Amazon, AMD and Micron illustrate an important relationship. Infrastructure investment can create demand for processors and memory, while the cloud operator must eventually earn an adequate return on that investment.
This is a business-model connection, not evidence of any particular supply contract between these companies. It explains why they can react differently to the same AI news: stronger spending may help suppliers while raising cash-flow questions for buyers.
There is a second connection: thirteen tickers do not necessarily mean thirteen independent risks. Apple, Walmart and payment networks all have exposure to consumer activity; the healthcare trio shares pricing and policy risks. Sector diversification helps, but shared economic drivers still matter.
8. Where Could Prices Go? Make the Assumptions Visible
For the next 6–12 months, my bias is to favor earnings upgrades over automatic valuation expansion. I see AMD and Micron as the more volatile growth/cycle exposures; Apple, Amazon and Lilly still need execution to justify expectations; payment networks offer a comparatively direct link to transaction growth. None is insulated from a market-wide repricing.
The following is illustrative valuation sensitivity, not an analyst target or a probability-weighted forecast. It shows how changes in the forward EPS estimate and forward P/E could translate into prices, using the reference snapshot above.
Illustrative price = reference price × (1 + change in forward EPS estimate) × (1 + change in forward P/E). The starting EPS estimate is normalized to 1; the exercise does not claim a measured current forward P/E or a consensus EPS forecast.
All changes are author-selected assumptions, not company guidance. Prices are rounded to whole dollars, exclude dividends and are not technical support/resistance levels. “Base” is a middle illustration, not the most likely outcome; outcomes can fall outside these scenarios.
Notice Micron's middle illustration: a 10% earnings upgrade paired with a 10% multiple decline produces a slightly lower price. Earnings growth alone does not guarantee a positive return.
9. Which Winner Still Has Something Left to Prove?🎁
The most interesting question is where the next earnings surprise could come from.
For $Advanced Micro Devices(AMD)$ and $Micron Technology(MU)$, I would watch demand durability and margin expectations. For $Apple(AAPL)$ and $Amazon.com(AMZN)$, monetization and cash generation matter. Lilly, $Johnson & Johnson(JNJ)$ and $AbbVie(ABBV)$ need continued portfolio execution; $Visa(V)$ and $MasterCard(MA)$ need transaction growth; $JPMorgan Chase(JPM)$ and $Berkshire Hathaway(BRK.B)$ need earnings quality; $Wal-Mart(WMT)$ needs profitable growth; $Exxon Mobil(XOM)$ needs resilient cash flow.
Tigers, which would you choose for the next 6–12 months: the AI leaders, healthcare growers, payment networks, or cash-generating giants—and what would change your mind?
For general information and discussion. Analyst targets can change, and the share-price scenarios depend on the conditions described. This article is not investment advice.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

**① MU:增长潜力更大。** AI服务器对HBM和高性能内存的需求持续增加,美光有机会受益于产品升级和供需改善。但内存行业具有周期性,我会重点关注DRAM价格、HBM订单和毛利率,避免在盈利高峰支付过高估值。
**② AMD:机会大,但预期也高。** 数据中心业务增长强劲,不过股价已经反映了不少乐观预期。未来必须通过实际出货、市场份额提升和利润增长来证明估值。
**③ Visa:长期确定性相对更高。** 全球电子支付和跨境交易增长能够持续支持收入,商业模式也不像AI基础设施那样需要巨额资本投入。
🚀 **我的策略:MU关注回调后的分批布局机会,V作为长期配置,AMD等待更合理的估值。**
**什么会改变我的判断?** 如果HBM供应快速增加、内存价格明显转弱,我会降低对MU的预期;如果AMD持续提升AI芯片市场份额并改善利润率,我会重新评估其吸引力。
**结论:下一轮反弹,我更看好盈利预期持续上修的企业,而不是单纯依靠估值扩张的股票。**
**真正的赢家,不是今年涨得最多的公司,而是明年还能不断超越市场预期的公司!📈**
我把13只股票分成四组来看:
1. AI芯片:AMD、MU
AMD: 受惠AI服务器和数据中心需求,增长潜力大。
MU美光: 受惠HBM及AI内存需求,但半导体有周期性,需求和价格可能反转。
增长潜力高,但股价波动也大,不适合盲目追高。
2. 医疗保健:LLY、JNJ、ABBV
LLY:减肥药及糖尿病药物增长强劲。
JNJ:业务较多元,但诉讼风险仍需关注。
ABBV:新药Skyrizi、Rinvoq接棒旧药,值得观察。
适合关注长期医疗需求,但要留意估值和药物竞争。
3. 消费及支付:AAPL、AMZN、WMT、V、MA
这些公司主要靠消费者消费、云服务及支付交易赚钱。
Visa和Mastercard的商业模式相对轻资产,不需要像银行一样承担大量贷款风险。
4. 现金流及金融:JPM、BRK.B、XOM
JPM:银行业务强,但要留意信贷风险。
BRK.B:业务多元,重视长期资本配置。
XOM:现金流和股息有吸引力,但受油价影响。
我的投资选择
如果看未来6–12个月,我会这样排序:
1. 长期稳定: V、MA、BRK.B。
2. AI增长: AMD、MU。
3. 医疗增长: LLY、ABBV。
4. 股息及现金流: XOM。
考虑到长期投资不能只追求股价上涨,我更重视盈利、现金流和合理估值。
最后记住:涨幅最大的股票,不一定是下一阶段最值得买的股票。
真正要寻找的是:未来盈利还有增长空间,而且目前股价没有提前透支太多预期的公司。